Company intelligence / Profile preview

CBATEG

Ownership: Private
Development stage: Other

Overview

CBATEG is a biotechnology company focused on developing next-generation cell therapies for the treatment of cancer. The company utilizes a proprietary platform to engineer T cells with specific gamma-delta T cell receptors (TEGs), aiming to combine the precision of alpha-beta T cells with the broad tumor-recognition capabilities of gamma-delta T cells. Their primary focus is on addressing hematological malignancies and potentially solid tumors where traditional CAR-T therapies face limitations. CBATEG's pipeline is currently in the pre-clinical stage, with a focus on optimizing cell persistence and tumor infiltration.

Therapeutic areas: Oncology
Modalities: Cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on CBATEG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBATEG.

Explore the full profile